Drug Database
HE

hepatitis A vaccine (Havisure)

✓ Approved

Indian Immunologicals · Vaccine · Vaccine

What is hepatitis A vaccine?

hepatitis A vaccine is a vaccine developed by Indian Immunologicals. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesHavisure
CompanyIndian Immunologicals
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Indian Immunologicals

Therapeutic Indications

hepatitis A vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

Related Research Articles

PubMedMedicine2026-05-30

Acute hepatitis B infection escaping vaccination: A case report.

Leonhard Sonja E SE, Fioole Daphne N DN, Benschop Kimberley S M KSM, Willems Roel P J RPJ et al.

Hepatitis B virus (HBV) is an important cause of acute and chronic infectious hepatitis globally. Vaccines against HBV are widely available and generally lead to lifelong protection against chronic infection, disease, and infectivity. Vaccine failure, in which a person fails to form sufficiently high antibody titers, occurs in 5% to 10% of the population. Vaccine failure due to mutations in the virus, enabling vaccine escape, on the other hand, is very rare. A 72-year-old man presented with heartburn complaints. In clinical examination, an enlarged liver was found, and subsequent testing showed abnormal liver function. He was fully vaccinated against HBV. Positive test results for hepatitis B surface antigen, immunoglobulin G and immunoglobulin M antibodies against hepatitis B core antigen, and antibodies against hepatitis B e and surface antigen were found. HBV DNA was positive (14,000 IU/mL). These results indicated an acute HBV infection. A rare mutation in the S-gene of HBV, D144A, was found. The patient recovered without treatment. We describe a case of acute HBV infection in a fully vaccinated person with high post-vaccination titers due to a rare mutation in the S-gene of HBV, which has previously been associated with vaccine escape. We describe the epidemiology of such mutations and the public health consequences of discovering such a strain in the community.

PMID 42216401
Read full article →
PubMedAntiviral research2026-05-30

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Bertoletti Antonio A, Ambike Shubhankar S SS, Le Bert Nina N, Binayke Akshay A AA

Over 30 years of therapeutic vaccine development have yet to deliver a functional cure for chronic HBV infection. Despite promising preclinical data, most therapeutic vaccine preparations have largely failed to restore HBV-specific B and T cell immunity in a clinically meaningful way. Only a recent trial combining siRNA Elebsiran and PEG-IFN-α reported a remarkable ∼50% HBsAg loss rate in chronic HBV patients who responded to a therapeutic vaccine based on PreS1/S2/S recombinant protein (BRII-179) administered prior to the trial. Here we dissect the immunological basis for this differential clinical outcome, and chart a path toward the next generation of effective therapeutic HBV vaccines.

PMID 42214471
Read full article →
PubMedHuman vaccines & immunotherapeutics2026-05-30

Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review.

Avermark Helena H, Tzirita Sofia S, Radix Erik E, Sun Sunjuri S et al.

Men who have sex with men (MSM) and transgender persons are disproportionately affected by HPV-related disease. The HPV vaccine effectively prevents infection, but vaccine uptake remains suboptimal in this group. Thus, this systematic review aimed to synthesize the literature on interventions and strategies implemented to increase HPV vaccine confidence and uptake among MSM and transgender persons. Six databases were searched in May 2025. We assessed risk of bias and extracted and descriptively summarized key data through narrative synthesis and content analysis. Sixteen articles reporting on eight interventions were identified, all implemented in high-income settings. The interventions can be broadly categorized into two types: strategies to integrate HPV vaccination into existing health services and digital interventions aimed at generating vaccine demand. Overall, evidence remains limited on interventions to increase HPV vaccine uptake in these groups, particularly studies focusing on the needs of transgender persons.

PMID 42216453
Read full article →
PubMedComputational biology and chemistry2026-05-30

Contriving multiepitope vaccine for breast cancer by targeting the estrogen receptor using in-silico method.

Shah Fahad Hassan FH, Cho Jung Sig JS, Na Jae Uk JU, Chung Hyung-Joo HJ et al.

Breast cancer is an invasive cancer that arises either in ductal epithelial cells or lobules of the glandular tissues of the breast. The main culprit behind this misery in most cases is Estrogen receptor which allows binding of estrogen protein that helps in the proliferation, differentiation, and metastasis of breast cells. The present study designed multi-epitope B-cell stimulating vaccine by using estrogen receptor alpha as a template for epitope prediction. The predicted epitopes were checked for antigenicity, and toxicity using Vaxijen, Aller-Pred and Toxin-Pred. The final vaccine construct was used for the physicochemical prediction, In-silico immunosimulation, structure modeling and energy and structural refinement procedures followed by molecular docking with toll-like receptors and molecular dynamics. The obtained sequence of multi-epitope vaccine construct had adequate physiochemical and immunological properties. The structure constructed from the vaccine sequence had an appropriate secondary and 3-dimensional structure. The predicted 3D structure of the vaccine construct showed favorable interactions with toll-like receptors 1, 2, and 4, suggesting its potential to stimulate innate and adaptive immune responses. Our study proposes a promising vaccine candidate for breast cancer caused by the activity of estrogen receptor that can stimulate both innate and adaptive immune response to prevent the proliferation and progression.

PMID 42214855
Read full article →
PubMedHuman vaccines & immunotherapeutics2026-05-30

Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China.

Zhou Yuxuan Y, Tang Rong R, Wei Mingwei M, Peng Xinglu X et al.

This study evaluates the post-marketing safety profile of a Haemophilus influenzae Type b (Hib) conjugate vaccine in children aged 3 months to 5 y in China. A prospective, observational, multi-center, post-marketing safety surveillance study of a monovalent Hib conjugate vaccine manufactured by Chengdu Olymvax Biotechnology Inc. was conducted across 20 districts in Jiangsu Province, China, from June 2020 to December 2021. The study enrolled 2,714 children in the active surveillance group and 6,347 children in the passive surveillance group. For active surveillance, guardians recorded all adverse events occurring within 30 d after each vaccine dose in diary cards, regardless of suspected causality. Serious adverse events were captured through spontaneous guardian reports or through regular investigator follow-up from the first dose through 6 months after completion of the primary Hib conjugate vaccine series. During passive surveillance, suspected adverse events following immunization (AEFI) of the Olymvax Hib vaccine were registered and reported through China National Adverse Event Following Immunization (AEFI) Surveillance System. Active surveillance revealed an overall adverse event incidence of 6.7% (181/2,714), with 6.3% (170/2,714) classified as adverse reactions, predominantly mild to moderate in severity (Grade 1-2: 6.0%; Grade 3: 0.3%). Passive surveillance identified a substantially lower adverse reaction incidence of 0.33% (21/6,347), with pyrexia (0.25%) being the most frequent. The AEFI incidence rate in passive surveillance was significantly lower than in active surveillance (P < .001). No vaccine-related serious adverse reactions were reported in either surveillance system. This post-marketing surveillance study confirms that the Hib conjugate vaccine demonstrates a favorable safety profile in children aged 3 months to 5 y, with no safety-associated risks identified.

PMID 42216576
Read full article →
PubMedVirology2026-05-30

The rationale for universal use of a prophylactic Epstein-Barr virus vaccine.

Meirhaeghe Madeline R MR, Balfour Henry H HH

Epstein-Barr virus (EBV) was discovered in 1964 by examining cells from a malignant tumor under an electron microscope and as such became the first recognized human cancer virus. Shortly after that, EBV was shown to have infected at least 90% of adults worldwide with infectious mononucleosis being the common clinical manifestation of primary EBV infection. EBV is implicated in the causality of a plethora of malignancies and autoimmune diseases. Recent research studies have strengthened these associations. EBV associated diseases are an enormous global health problem and for that reason we are advocating for the universal use of a prophylactic EBV vaccine to prevent or reduce the severity of these EBV diseases. However, we are aware that a number of unanswered questions need to be addressed in order to maximize the potential benefit of such a vaccine. Perhaps the most important of these is whether an EBV vaccine given after primary EBV infection would confer any protection from the chronic sequelae attributed to EBV.

PMID 42214819
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hepatitis A vaccine